Press release
Investigation announced for Investors in Ocugen, Inc. (NASDAQ: OCGN) over possible Violations of Securities Laws
An investigation for investors in Ocugen, Inc. (NASDAQ: OCGN) shares over potential securities laws violations by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) concerning whether a series of statements by Ocugen, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Malvern, PA based Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.
On May 26, 2021, Ocugen, Inc. announced its plan to submit an Emergency Use Authorization (EUA) application for COVAXIN, a COVID-19 vaccine, to the U.S. Food & Drug Administration (FDA) in June 2021.
Then on June 10, 2021, Ocugen, Inc. said it would no longer pursue a EUA for Covaxin and would instead aim to file for a full U.S. approval of the shot.
Shares of Ocugen, Inc. (NASDAQ: OCGN) declined from $11.01 per share on June 8, 2021 to $5.96 per share on June 14, 2021.
Those who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in Ocugen, Inc. (NASDAQ: OCGN) over possible Violations of Securities Laws here
News-ID: 2308142 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Ocugen
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investigation announced for Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) s …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.
Investors who are current long term investors in Ocugen, Inc. (NASDAQ: OCGN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: OCGN stocks follows a lawsuit filed against Ocugen, Inc. over alleged securities…
Lawsuit filed for Investors in shares of Ocugen, Inc. (NASDAQ: OCGN)
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit over alleged violations of Federal Securities Laws by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: August 17, 2021. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a clinical-stage…
Retinitis Pigmentosa (RP) Market 2025 : Ocugen, Inc., ReGenX Biosciences, LLC, S …
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, is a condition where patients typically loses ability to see at night in young years, side vision in middle age, and focal vision in later in his/her life due to relentless loss of cone photoreceptor cells. Proportions of retinal capacity, for example, the electroretinogram, demonstrate that photoreceptor capacity is decreased normally quite before symptomic night visual impairment, visual-field scotomas, or diminished visual sharpness…
Retinitis Pigmentosa (RP) Market | Ocugen, Inc., ReGenX Biosciences, LLC, Sucamp …
Global Retinitis Pigmentosa (RP) Market: Overview
Retinitis Pigmentosa (RP), an inherited retinal condition causing retinal degeneration and visual field loss, is a rare disease. Its initial symptoms are reduced night vision and loss of peripheral vision. It gradually causes blindness. There is no definitive cure for retinitis pigmentosa. Therefore, the market for treating this genetic disorder is vastly untapped. The available therapies apply various approaches such as stem cell therapy and…
Retinitis Pigmentosa (RP) Market | Amarantus BioScience Holdings, Inc., Ocugen, …
Global Retinitis Pigmentosa (RP) Market: Snapshot
Retinitis pigmentosa, in which patients usually lose night vision in teenage years, side vision in middle age, and central vision in later life because of steady loss of cone photoreceptor cells and rod. Measures of retinal function, such as the electroretinogram, indicate that photoreceptor function is reduced usually several years before visual-field scotomas, symptomic night blindness, or reduced visual acuity arise.
Get Sample Copy of…
